Table 1.

Disease states that may benefit from marine omega-3 supplementation

Study	Patient population	Dose of omega-3	Benefit
JELIS	18,645 hypercholesterolemic patients on statin therapy	1.8 g EPA	Significant 19% reduction in the primary endpoint
DART	2,033 men who experienced a first myocardial infarction (average time post-MI was 41 days)	~ 2.5 grams of EPA/week or 300 grams of fatty fish every week	Significant 29% reduction in total mortality in the first 2 years
GISSI-P	11,324 patents early after a myocardial infarction (< 3 months).	1-gram of marine omega-3s	Significant 20% decrease in all-cause mortality, 30% decrease in cardiovascular mortality and a 45% decrease in sudden cardiac death.
GISSI-HF	6,935 patients with chronic heart failure	1-gram of marine omega-3s	Significant 8% reduction in death or cardiovascular hospitalization, 9% reduction in all-cause mortality and 10% reduction in cardiovascular death
VITAL	25,871 patients over the age of 50 who had no prior history of cardiovascular disease.	1-gram of marine omega-3s	Significant 28% reduction in myocardial infarction, 50% reduction in death from myocardial infarction, 22% reduction in percutaneous coronary revascularization and a 17% reduction in total coronary heart disease.
ASCEND	15,480 diabetic patients without known atherosclerotic cardiovascular disease	1-gram of marine omega-3s	Significant 18% reduction in vascular death
REDUCE-IT	8,179 patients with established cardiovascular disease or diabetes with hypertriglyceridemia and at least one additional risk factor who had been receiving statin therapy.	4-grams of icosapent ethyl	Significant 25% reduction in the primary endpoint (composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina) and a significant 26% reduction in the key secondary efficacy endpoint of major adverse cardiovascular events (composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke).